Balance Sheet

v3.21.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2021
Sep. 30, 2020
Current Assets:    
Cash and cash equivalents $ 103,697,162 $ 13,859,748
Prepaid expenses 1,277,029 122,237
Total Current Assets 104,974,191 13,981,985
Property and equipment, net 1,272 1,577
Operating lease right-of-use asset, net 906,092 986,204
Other Assets:    
Deposits 38,062 57,093
In-process research and development 19,400,000 19,400,000
Goodwill 9,346,796 9,346,796
Total Other Assets 28,784,858 28,803,889
Total Assets 134,666,413 43,773,655
Current Liabilities:    
Accounts payable 1,132,877 1,856,235
Accrued expenses 240,610 164,040
Accrued compensation 1,172,375 1,654,919
Accrued interest 97,877 89,970
Notes payable – related parties 172,970 172,970
Operating lease liability 167,937 158,999
Total Current Liabilities 2,984,646 4,097,133
Note payable – paycheck protection program 164,583 164,583
Deferred tax liability 4,985,800 4,985,800
Operating lease liability – non current 769,218 855,471
Total Liabilities 8,904,247 10,102,987
Commitments and Contingencies
Stockholders' Equity:    
Preferred stock – $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock – $0.001 par value; 200,000,000 shares authorized; 134,701,219 and 55,576,996 shares issued and outstanding at March 31, 2021 and September 30, 2020, respectively 134,701 55,577
Additional paid-in capital 210,289,813 104,208,958
Accumulated deficit (85,262,728) (70,593,867)
Total Citius Pharmaceuticals, Inc. Stockholders' Equity 125,161,786 33,670,668
Non-controlling interest 600,380
Total Equity 125,762,166 33,670,668
Total Liabilities and Equity $ 134,666,413 $ 43,773,655

Source